• 1
    McLean IW, Burnier M, Zimmerman L, Jakobiec F. Armed Forces Institute of Pathology atlas of tumor pathology: tumors of the eye and ocular adnexa. Washington, DC: Armed Forces Institute of Pathology, 1994.
  • 2
    Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993; 85: 11211128.
  • 3
    Advani SH, Rao SR, Iyer RS, Pai SK, Kurkure PA, Nair CN. Pilot study of sequential combination chemotherapy in advanced and recurrent retinoblastoma. Med Pediatr Oncol. 1994; 22: 125128.
  • 4
    Byrne J, Fears TR, Whitney C, Parry DM. Survival after retinoblastoma: long-term consequences and family history of cancer. Med Pediatr Oncol. 1995; 24: 160165.
  • 5
    Kaste SC, Chen G, Fontanesi J, Crom DB, Pratt CB. Orbital development in long-term survivors of retinoblastoma. J Clin Oncol. 1997; 15: 11831189.
  • 6
    Hicklin DJ, Marincola FM, Ferrone S. HLA Class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today. 1999; 5: 178186.
  • 7
    Seliger B, Maeurer MJ, Ferrone S. Antigen processing machinery breakdown and tumor growth. Immunol Today. 2000; 21: 455464.
  • 8
    Fournier GA, Sang DN, Albert DM, Craft JL. Electron microscopy and HLA expression of a new cell line of retinoblastoma. Invest Ophthalmol Vis Sci. 1987; 28: 690699.
  • 9
    Barez S, Boumpas DT, Percopo CM, Anastassiou ED, Hooks JJ, Detrick B. Modulation of major histocompatibility complex Class 1 genes in human retinoblastoma cells by interferons. Invest Ophthalmol Vis Sci. 1993; 34: 26132621.
  • 10
    Detrick B, Chader GJ, Katz N, et al. Evaluation of Class II antigen expression and cellular differentiation in retinoblastoma [abstract]. Invest Ophthalmol Vis Sci. 1988; 29(Suppl): 340a.
  • 11
    Detrick B, Chader GJ, Rodrigues M, Kyritsis AP, Chan CC, Hooks JJ. Coexpression of neuronal, glial, and major histocompatibility complex Class II antigens on retinoblastoma cells. Cancer Res. 1988; 48: 16331641.
  • 12
    Sang DN, Anderson DJ. Retinoblastoma. HLA expression induced by retinoic acid. Retina. 1983; 3: 206211.
  • 13
    Ksander BR, Geer DC, O'Brien JM, et al. Retinoblastoma specific T cells fail to eliminate intraocular tumors [abstract]. Invest Ophthalmol Vis Sci. 1993; 34(Suppl): 974a.
  • 14
    Ksander BR, Geer DC, Murray TG. Studies of tumor infiltrating lymphocytes from human retinoblastoma [abstract]. Proc Am Assoc Cancer Res. 1993; 34: 488a.
  • 15
    Biswas J, Das D, Krishnakumar S, Shanmugam MP. Histopathologic analysis of 232 eyes with retinoblastoma conducted in an Indian tertiary-care ophthalmic center. J Pediatr Ophthalmol Strabismus. 2003; 40: 265267.
  • 16
    Schillng H, Yang H, Havers G, Bornfeld N, Schuler A. Changes of the retinal pigment epithelium and choroidal invasion in 297 enucleated eyes with retinoblastoma—histologic staging and metastatic rate [abstract]. Presented at the Tenth International Congress of Ocular Oncology, Amsterdam, The Netherlands, June 17–21, 2001.
  • 17
    Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol. 1986; 137: 22992306.
  • 18
    Lampson LA, Fisher CA, Whelan JP. Striking paucity of HLA-A, B, C and β2-microglobulin on human neuroblastoma cell lines. J Immunol. 1983; 130: 24712478.
  • 19
    Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, Ferrone S. Characterization of anti-HLA Class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods. 1993; 161: 239256.
  • 20
    Kishore R, Hicklin DJ, Dellaratta DV, et al. Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. Tissue Antigens. 1998; 51: 129140.
  • 21
    International Histocompatibility Working Group. HLA expression in cancer [monograph online]. Available from URL:[accessed 9 Dec 2003].
  • 22
    Krishnakumar S, Abhyankar D, Sundaram AL, Pushparaj V, Shanmugam MP, Biswas J. Major histocompatibility antigens and antigen processing molecules in uveal melanoma. Clin Cancer Res. 2003; 9: 41594164.
  • 23
    Giorda E, Sibilio L, Martayan A, et al. The antigen processing machinery of Class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. Cancer Res. 2003; 63: 41194127.
  • 24
    Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol. 1996; 41: 215228.
  • 25
    Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development Immunol Today. 1993; 14: 491499.
  • 26
    Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defense strategy. Nature. 1986; 319: 675678.
  • 27
    Lanier LL, Corliss B, Phillips JH. Arousal and inhibition of human NK cells. Immunol Rev. 1997; 155: 145154.
  • 28
    Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity. 1997; 6: 655661.
  • 29
    Long EO, Burshtyon DN, Clark WP, et al. Killer cell inhibitory receptors: diversity, specificity and function. Immunol Rev. 1997; 155: 135144.
  • 30
    Garrido F, Ruiz-Cabello F, Cabrera T, et al. Implications for immunosurveillance of altered HLA Class I phenotypes in human tumours. Immunol Today. 1997; 18: 8995.
  • 31
    Honma S, Tsukuda S, Honda S, et al. Biological significance of selective loss of HLA Class I allelic product expression in squamous-cell carcinoma of the uterine cervix. Int J Cancer. 1994; 57: 650655.
  • 32
    Keating PJ, Cromme FV, Duggan-Keen M, et al. Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. Br J Cancer. 1995; 72: 405411.
  • 33
    Altomonte M, Fonsatti E, Visintin A, Maio M. Targeted therapy of solid malignancies via HLA Class II antigens: a new biotherapeutic approach? Oncogene. 2003; 22: 65646569.
  • 34
    Moretti S, Pinzi C, Berti E, et al. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3-integrin expression. Melanoma Res. 1997; 7: 313321.
  • 35
    Trieb K, Lechleitner T, Lang S, et al. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma. Pathol Res Pract. 1998; 194: 679684.
  • 36
    Diederichsen AC, Stenholm AC, Kronborg O, et al. Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers. Int J Cancer. 1998; 79: 283287.
  • 37
    Hilders CG, Houbiers JG, van Ravenswaay Claasen HH, et al. Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Lab Invest. 1993; 69: 651659.
  • 38
    Coleman N, Stanley MA. Analysis of HLA-DR expression on keratinocytes in cervical neoplasia. Int J Cancer. 1994; 56: 314319.
  • 39
    Cromme FV, Meijer CJ, Snidjers PJ, et al. Analysis of MHC Class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. Br J Cancer. 1993; 67: 13721380.
  • 40
    Jackson PA, Green MA, Marks CG, et al. Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. Gut. 1996; 38: 8589.
  • 41
    Matsushita K, Takenouchi T, Kobayashi S, et al. HLA-DR antigen expression in colorectal carcinomas: influence of expression by IFN-gamma in situ and its association with tumor progression. Br J Cancer. 1996; 73: 644648.
  • 42
    Abhyankar D, Lakshmi SA, Pushparaj V, Biswas J, Krishnakumar S. HLA Class II antigen expression in conjunctival precancerous lesions and squamous cell carcinomas. Curr Eye Res. 2003; 27: 151155.
  • 43
    Schurmans LR, Diehl L, den Boer AT, et al. Rejection of intraocular tumors by CD4+ T cells without induction of phthisis. J Immunol. 2001; 167: 58325837.
  • 44
    Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med. 1982; 155: 768782.
  • 45
    Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex Class II negative tumors. J Exp Med. 1998; 187: 693702.
  • 46
    Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T-cell help. J Exp Med. 1997; 186: 6570.
  • 47
    Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol. 2002; 47: 116.
  • 48
    Shanmugam MP, Lakshmi AS, Biswas J, Krishnakumar S. Prognostic significance of Fas expression in retinoblastoma. Ocul Immunol Inflamm. 2003; 11: 107113.
  • 49
    Krishnakumar S, Lakshmi AS, Biswas J, Shannmugam MP. Nm23 expression in retinoblastoma. Ocul Immunol Inflamm. In press.
  • 50
    Lakshmi AS, Pushparaj V, Krishnamurthy V, Shanmugam MP, Biswas J, Krishnakumar S. Tetraspanin protein KAI1 expression in retinoblastoma. Br J Ophthalmol. In press.